Oppenheimer Raises Humana (HUM) Price Target to $525

Oppenheimer has reiterated its Outperform rating on Humana, raising the price target to $525, a 25.49% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:08 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer raised its price target on Humana Inc. ($HUM) to $525 from $475 on October 12, 2026, and rates the stock "Outperform".

Since the rating, $HUM is down 4.7% to date (from the $433.50 close on Oct 12, 2026).

HUM Humana Inc.

$413.16 +57.38% year to date

Daily close · Oct 16, 2026

Key Points

On October 12, 2026, Oppenheimer reiterated its Outperform rating on Humana Inc. (NYSE: HUM) and increased the price target from $475 to $525.
Oppenheimer's $525 price target implies 25.49% upside from Humana Inc.'s ($HUM) current $418.36 share price.
Humana shares recently traded around $418.36, which is below the average analyst target of $465.13 and 20.3% below Oppenheimer's new target.
The company reported a revenue of $145.7 billion over the trailing twelve months, with a net margin of 0.9%.

Get $HUM trade alerts by text

We text you when insiders, Congress or big funds trade $HUM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Humana Inc. alert may contain errors. Disclosures

Oppenheimer has reiterated its Outperform rating on Humana Inc. (NYSE: HUM) and raised the price target from $475 to $525 on October 12, 2026. This updated target suggests a more optimistic outlook for the healthcare company, which recently traded around $418.36.

Other Institutional Activity in Humana Inc.

Dodge & Cox Inc. trimmed its stake in Humana by 440,438 shares, bringing its total to 10,940,380 shares valued at about $4.5 billion. Meanwhile, Blackrock Inc. added 218,270 shares, increasing its holdings to 10,417,803 shares worth approximately $4.3 billion. Vanguard Capital Management LLC saw a slight increase, adding 4,703 shares for a total of 7,843,620 shares valued at around $3.2 billion. Additionally, Vanguard Portfolio Management LLC and State Street Corporation both made small adjustments, ending with 5,818,956 shares and 5,457,072 shares, respectively.

Humana Inc. Stock Down 2.1%

Humana shares are currently trading above their 50-day moving average by about 6.5% and 39.3% above the 200-day moving average. However, they are about 8.4% below the 52-week high of $456.50. The recent price is also 10.1% below the average analyst price target of $465.13, indicating potential upside.

12-month forecast

$HUM price target

Humana Inc. daily closes and this analyst's $525 target. Not advice.

Recent Earnings

For the trailing twelve months, Humana reported revenue of $145.7 billion and an earnings per share (EPS) of $10.88. The company has shown a year-over-year revenue growth of 26.2%. The next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Humana Inc.

On February 23, 2026, Officer Sanjay K Shetty purchased 810 shares at an average price of $185.20, totaling around $150,016. This transaction occurred before the recent analyst calls and reflects confidence in the company's future.

Analysts Set New Price Targets

On October 12, 2026, both Oppenheimer and Raymond James maintained their ratings on Humana, with Oppenheimer setting a new price target of $525 and Raymond James upgrading to Outperform with a target of $520. Barclays also maintained its Overweight rating with a price target increase to $582. The consensus among analysts gives Humana a mean price target of $465.13 based on 24 opinions.

About Humana Inc.

Humana Inc. provides medical and specialty insurance products across the United States. The company operates in two main segments: Insurance and CenterWell, focusing on improving health outcomes for its members.

Bottom Line

Investors will be watching for the upcoming earnings report on November 6, 2026, to see how Humana's performance aligns with analyst expectations. Oppenheimer's reiteration of its rating and price target could signal continued optimism about the company's prospects.